Champions Oncology, Inc. (CSBR) Stock

Champions Oncology, Inc. (CSBR) is a Healthcare stock trading at $5.06 (as of 2026-08-21), with a market capitalization of $70.30M and a trailing P/E of 17.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Champions Oncology, Inc. provides technology and software offerings aimed at personalizing oncology drug development and use in the United States. Its Tumorgraft Technology Platform uses implanted human tumors in immune-deficient mice, supported by Translational Oncology Solutions for pharmaceutical and biotechnology customers and the Lumin Bioinformatics subscription software platform for research and clinical study-derived data.

Understand Champions Oncology, Inc.: how it makes money

Champions Oncology develops and sells technology solutions based on its Tumorgraft Technology Platform to personalize oncology drug development and use, generating revenue from areas including core studies, research services, and data licensing.

The profit model is monetizing the Tumorgraft Technology Platform through paid customer engagement, where retention (Lumen Renewal Rate) supports recurring Lumen licensing, alongside one-off revenue tied to core studies and research services.

Revenue by segment (latest quarter)
Core Study$0.0B
Research Svcs$0.0B
Data Licenses$0.0B

Business quality (Weak): Latest-period results show very small revenue amounts with negative operating margin, so trends in customer retention and product usage metrics are likely the most important read-through, but the dataset here is limited.

Bull case

  • Retention signal from Lumen: Lumen Renewal Rate is 80 percent, suggesting customers renew their Lumen licenses.
  • Commercial activity beyond pure data licensing: Core Study Revenue is 0.02 USD_B and Research Services Revenue is 0.01 USD_B in the latest period, while Data Licensing Revenue is 0.0 USD_B.
  • Gross profit positive (despite operating loss): Gross margin is 46.7 percent, even though operating margin is -1.7 percent.

Bear case

  • Operating loss: Operating margin is -1.7 percent in the latest period.
  • Very small revenue base in the latest period: Total revenue_b is 0.0 (with segment components summing to 0.03 USD_B from Core Study and Research Services), which can make results more sensitive to small changes.
  • Data licensing not contributing in the latest period: Data Licensing Revenue is 0.0 USD_B in the latest period.
Valuation — source: SEC EDGAR (first-party)
Price$5.06
Market Cap$70.30M
P/E Ratio17.6
EV / EBITDA12.3
Price / Book17.28
Price / Sales1.12
FCF Yield-4.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$59.42M
Net Margin-2.0%
Revenue Growth (YoY)4.4%
EPS Growth (YoY)-123.5%
FCF Growth (YoY)-172.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-0.33 (distress)
Valuation vs Sector & Industry
Stock P/E17.6
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
vs Sector-18.9%
vs Industry2.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBATTERY MANAGEMENT CORP. ($13.92M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORobert Brainin
Employees210
CountryUS
IPO Date2007-02-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • ProKidney Corp. (PROK)
  • Atara Biotherapeutics, Inc. (ATRA)
  • Cardiff Oncology, Inc. (CRDF)
  • eXoZymes, Inc. (EXOZ)
  • INmune Bio, Inc. (INMB)
  • ImageneBio Inc (IMA)
  • MiNK Therapeutics, Inc. (INKT)
  • Scilex Holding Company (SCLX)
CSBR earnings history · CSBR institutional & insider holders · CSBR KPIs & operating metrics · CSBR financials · CSBR investor presentations & press releases · CSBR SEC filings · CSBR peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.